Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities.

To commemorate the 50th anniversary of the Society of Toxicology, this special edition article reviews the history and current scope of xenobiotic metabolism and transport, with special emphasis on the discoveries and impact of selected "xenobiotic receptors." This overall research realm has witnessed dynamic development in the past 50 years, and several of the key milestone events that mark the impressive progress in these areas of toxicological sciences are highlighted. From the initial observations regarding aspects of drug metabolism dating from the mid- to late 1800's, the area of biotransformation research witnessed seminal discoveries in the mid-1900's and onward that are remarkable in retrospect, including the discovery and characterization of the phase I monooxygenases, the cytochrome P450s. Further research uncovered many aspects of the biochemistry of xenobiotic metabolism, expanding to phase II conjugation and phase III xenobiotic transport. This led to hallmark developments involving integration of genomic technologies to elucidate the basis for interindividual differences in response to xenobiotic exposures and discovery of nuclear and soluble receptor families that selectively "sense" the chemical milieu of the mammalian cell and orchestrate compensatory changes in gene expression programming to accommodate complex xenobiotic exposures. This review will briefly summarize these developments and investigate the expanding roles of xenobiotic receptor biology in the underlying basis of toxicological response to chemical agents.

[1]  A. Y. Lu,et al.  Immunochemical evidence for six forms of rat liver cytochrome P450 obtained using antibodies against purified rat liver cytochromes P450 and P448. , 1976, Molecular pharmacology.

[2]  Jifeng Zhang,et al.  Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[3]  T. Willson,et al.  Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. , 2006, Cancer research.

[4]  P. Watkins,et al.  Hepatic dysfunction associated with troglitazone. , 1998, The New England journal of medicine.

[5]  F. Gonzalez,et al.  Ube2l3 gene expression is modulated by activation of the aryl hydrocarbon receptor: implications for p53 ubiquitination. , 2010, Biochemical pharmacology.

[6]  K. Bock,et al.  Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. , 2009, Biochemical pharmacology.

[7]  Ramalinga Kuruba,et al.  A Functional Cross-Talk between Liver X Receptor-α and Constitutive Androstane Receptor Links Lipogenesis and Xenobiotic Responses , 2010, Molecular Pharmacology.

[8]  K. Morimura,et al.  Peroxisome Proliferator-Activated Receptor α Regulates a MicroRNA-Mediated Signaling Cascade Responsible for Hepatocellular Proliferation , 2007, Molecular and Cellular Biology.

[9]  T. Willson,et al.  Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  G. Fink,et al.  Loss of the Aryl Hydrocarbon Receptor Induces Hypoxemia, Endothelin-1, and Systemic Hypertension at Modest Altitude , 2008, Hypertension.

[11]  P. Demoly,et al.  [Transgenic mice]. , 1992, Annales de dermatologie et de venereologie.

[12]  M. Parker,et al.  Structure and function of glutathione S-transferases. , 1994, Biochimica et biophysica acta.

[13]  C. Glass,et al.  Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells , 2010, Nature Reviews Immunology.

[14]  D. Moore,et al.  Meclizine is an agonist ligand for mouse constitutive androstane receptor (CAR) and an inverse agonist for human CAR. , 2004, Molecular endocrinology.

[15]  W. Levin,et al.  Studies on the induction of CO-binding pigments in liver microsomes by phenobarbital and 3-methylcholanthrene. , 1967, Biochemical and biophysical research communications.

[16]  R. Wortmann,et al.  Myotoxicity associated with lipid-lowering drugs , 2007, Current opinion in rheumatology.

[17]  Paul B Watkins,et al.  Idiosyncratic Liver Injury: Challenges and Approaches , 2005, Toxicologic pathology.

[18]  S. O’Rahilly,et al.  PPAR gamma and human metabolic disease. , 2006, The Journal of clinical investigation.

[19]  S. Kliewer,et al.  The nuclear xenobiotic receptor CAR: structural determinants of constitutive activation and heterodimerization. , 2004, Molecular cell.

[20]  F. Gonzalez,et al.  PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. , 2008, Toxicology.

[21]  T. Brodie,et al.  PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  C. Bradfield,et al.  The Aryl Hydrocarbon Receptor sans Xenobiotics: Endogenous Function in Genetic Model Systems , 2007, Molecular Pharmacology.

[23]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[24]  G. Perdew,et al.  ERα-AHR-ARNT Protein-Protein Interactions Mediate Estradiol-dependent Transrepression of Dioxin-inducible Gene Transcription* , 2005, Journal of Biological Chemistry.

[25]  S. Momohara,et al.  Serum amyloid A activates nuclear factor-kappaB in rheumatoid synovial fibroblasts through binding to receptor of advanced glycation end-products. , 2008, The Journal of rheumatology.

[26]  Y. Wan,et al.  PPAR-gamma regulates osteoclastogenesis in mice. , 2007, Nature medicine.

[27]  L. Pedersen,et al.  Structure and function of sulfotransferases. , 2001, Archives of biochemistry and biophysics.

[28]  L. Lovat,et al.  Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein , 2001, The Lancet.

[29]  Vázquez Jj,et al.  Liver-cell adenoma in an epileptic man on barbiturates , 1989 .

[30]  R. Schears Acute liver failure in the United States. , 2003, Annals of internal medicine.

[31]  A. Akintobi,et al.  2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces matrix metalloproteinase (MMP) expression and invasion in A2058 melanoma cells. , 2006, Toxicology and applied pharmacology.

[32]  David Y. Lai,et al.  PPARα Agonist-Induced Rodent Tumors: Modes of Action and Human Relevance , 2003 .

[33]  J. Peters,et al.  Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[34]  J. Ward,et al.  Diminished Hepatocellular Proliferation in Mice Humanized for the Nuclear Receptor Peroxisome Proliferator-Activated Receptor α , 2004, Cancer Research.

[35]  J. Lahtela,et al.  Enzyme Inducers Improve Insulin Sensitivity in Non-insulin-dependent Diabetic Subjects , 1985, Diabetes.

[36]  T. Willson,et al.  Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines , 2007 .

[37]  A. Burdick,et al.  The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[38]  S. Wakil,et al.  Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease , 2009, Proceedings of the National Academy of Sciences.

[39]  H. Matsuo,et al.  Peroxisome proliferators and retinoids affect JEG-3 choriocarcinoma cell function. , 1994, Endocrinology.

[40]  L. Birnbaum,et al.  Non-carcinogenic effects of TCDD in animals , 2000, Food additives and contaminants.

[41]  W. Wahli,et al.  Polarity and Specific Sequence Requirements of Peroxisome Proliferator-activated Receptor (PPAR)/Retinoid X Receptor Heterodimer Binding to DNA , 1997, The Journal of Biological Chemistry.

[42]  S. Auerbach,et al.  Di(2-ethylhexyl) phthalate Is a Highly Potent Agonist for the Human Constitutive Androstane Receptor Splice Variant CAR2 , 2009, Molecular Pharmacology.

[43]  J. Miller,et al.  The metabolism of methylated aminoazo dyes. V. Evidence for induction of enzyme synthesis in the rat by 3-methylcholanthrene. , 1956, Cancer research.

[44]  J. Kuroda,et al.  Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. , 2006, European journal of pharmacology.

[45]  I. Issemann,et al.  The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. , 1992, The EMBO journal.

[46]  D. Moore,et al.  Role of the constitutive androstane receptor in xenobiotic-induced thyroid hormone metabolism. , 2005, Endocrinology.

[47]  W. Wahli,et al.  Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. , 1998, Endocrinology.

[48]  Jifeng Zhang,et al.  Nitrolinoleic acid: An endogenous peroxisome proliferator-activated receptor γ ligand , 2005 .

[49]  T. Willson,et al.  Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)—synthesis and biological activity , 2003 .

[50]  Jeffrey M Peters,et al.  Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in cell proliferation and cancer. , 2009, Biochimica et biophysica acta.

[51]  M. Negishi,et al.  The roles of nuclear receptors CAR and PXR in hepatic energy metabolism. , 2008, Drug metabolism and pharmacokinetics.

[52]  Margaret S. Wu,et al.  Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological Effects* , 1999, The Journal of Biological Chemistry.

[53]  M. Q. Kemp,et al.  Cyclooxygenase-2 Promoter Activation by the Aromatic Hydrocarbon Receptor in Breast Cancer MCF-7 Cells: Repressive Effects of Conjugated Linoleic Acid , 2007, Nutrition and cancer.

[54]  T. Sueyoshi,et al.  Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. , 2001, Annual review of pharmacology and toxicology.

[55]  G. Perdew,et al.  Nuclear receptor coactivator SRC-1 interacts with the Q-rich subdomain of the AhR and modulates its transactivation potential. , 1999, Gene expression.

[56]  A. Buchmann,et al.  The effect of connexin32 null mutation on hepatocarcinogenesis in different mouse strains. , 1999, Carcinogenesis.

[57]  W. Wahli,et al.  Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. , 1997, Molecular endocrinology.

[58]  M. Rao,et al.  Hepatocellular carcinomas in acatalasemic mice treated with nafenopin, a hypolipidemic peroxisome proliferator. , 1976, Cancer research.

[59]  Christine Dreyer,et al.  Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors , 1992, Cell.

[60]  P. Meier,et al.  Coordinate transcriptional regulation of transport and metabolism. , 2005, Methods in enzymology.

[61]  Hongbing Wang,et al.  Human Constitutive Androstane Receptor Mediates Induction of CYP2B6 Gene Expression by Phenytoin* , 2004, Journal of Biological Chemistry.

[62]  J. Lehmann,et al.  An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). , 1995, The Journal of biological chemistry.

[63]  K. Scotto Transcriptional regulation of ABC drug transporters , 2003, Oncogene.

[64]  M. J. Coon,et al.  Role of hemoprotein P-450 in fatty acid omega-hydroxylation in a soluble enzyme system from liver microsomes. , 1968, The Journal of biological chemistry.

[65]  T. Fujiwara,et al.  Characterization of New Oral Antidiabetic Agent CS-045: Studies in KK and ob/ob Mice and Zucker Fatty Rats , 1988, Diabetes.

[66]  X. Chen,et al.  Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[67]  C. Long,et al.  PPAR-γ activation fails to provide myocardial protection in ischemia and reperfusion in pigs , 2005 .

[68]  Jasmine Chen,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[69]  Richard E. Peterson,et al.  The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. , 2009, Biochemical pharmacology.

[70]  W. Xie,et al.  Pregnane X Receptor and Constitutive Androstane Receptor at the Crossroads of Drug Metabolism and Energy Metabolism , 2010, Drug Metabolism and Disposition.

[71]  W. Sabbagh,et al.  SXR, a novel steroid and xenobiotic-sensing nuclear receptor. , 1998, Genes & development.

[72]  Peter J. Brown,et al.  Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ , 1997 .

[73]  T. Misaka,et al.  Dietary flavonoids activate the constitutive androstane receptor (CAR). , 2010, Journal of agricultural and food chemistry.

[74]  T. Pineau,et al.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators , 1995, Molecular and cellular biology.

[75]  L. Lasagna Detoxication mechanisms. The metabolism and detoxication of drugs, toxic substances and other organic compounds , 1961 .

[76]  A. Burdick,et al.  The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. , 2006, Cellular signalling.

[77]  A. Kong,et al.  Induction of phase I, II and III drug metabolism/transport by xenobiotics , 2005, Archives of pharmacal research.

[78]  X. Coumoul,et al.  Nedd9/Hef1/Cas-L mediates the effects of environmental pollutants on cell migration and plasticity , 2009, Oncogene.

[79]  J. Buer,et al.  The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins , 2008, Nature.

[80]  Wolfgang Meissner,et al.  15-Hydroxyeicosatetraenoic Acid Is a Preferential Peroxisome Proliferator-Activated Receptor β/δ Agonist , 2010, Molecular Pharmacology.

[81]  Akane Kawamura,et al.  Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. , 2008, Toxicology.

[82]  C. Fontaine,et al.  Genomic and non-genomic interactions of PPARα with xenobiotic-metabolizing enzymes , 2004, Trends in Endocrinology & Metabolism.

[83]  S. Strom,et al.  The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. , 2010, Biochemistry.

[84]  J. Peters,et al.  Quantitative expression patterns of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) protein in mice. , 2008, Biochemical and biophysical research communications.

[85]  R. Hess,et al.  NATURE OF THE HEPATOMEGALIC EFFECT PRODUCED BY ETHYL-CHLOROPHENOXY-ISOBUTYRATE IN THE RAT , 1965, Nature.

[86]  Pierre Chambon,et al.  The nuclear receptor superfamily: a personal retrospect on the first two decades. , 2005, Molecular endocrinology.

[87]  W. J. Brammar,et al.  The ontogeny of peroxisome-proliferator-activated receptor gene expression in the mouse and rat , 1992, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[88]  T. Willson,et al.  PPARbeta/delta selectively induces differentiation and inhibits cell proliferation. , 2006, Cell death and differentiation.

[89]  Michael Dean,et al.  Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. , 2005, Annual review of genomics and human genetics.

[90]  M. Rao,et al.  Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. , 1993, The Journal of biological chemistry.

[91]  K. Eder,et al.  Clofibrate causes an upregulation of PPAR-{alpha} target genes but does not alter expression of SREBP target genes in liver and adipose tissue of pigs. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[92]  M. Gallo,et al.  Ah Receptor and NF-κB Interactions, a Potential Mechanism for Dioxin Toxicity* , 1999, The Journal of Biological Chemistry.

[93]  R. Ye,et al.  Cutting Edge: TLR2 Is a Functional Receptor for Acute-Phase Serum Amyloid A1 , 2008, The Journal of Immunology.

[94]  M. Negishi,et al.  Characterization of a Phenobarbital-responsive Enhancer Module in Mouse P450 Cyp2b10 Gene* , 1997, The Journal of Biological Chemistry.

[95]  T. Willson,et al.  Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines. , 2007, Carcinogenesis.

[96]  W. Xie,et al.  Receptor and Constitutive Androstane Receptor at the Crossroads of Drug Metabolism and Energy Metabolism , 2010 .

[97]  S. Safe,et al.  6-Methyl-1,3,8-trichlorodibenzofuran (MCDF) as an antiestrogen in human and rodent cancer cell lines: evidence for the role of the Ah receptor. , 1992, Toxicology and applied pharmacology.

[98]  M. Konopleva,et al.  2-Cyano-3,12-dioxoolean-1,9-dien-28-oic Acid and Related Compounds Inhibit Growth of Colon Cancer Cells through Peroxisome Proliferator-Activated Receptor γ-Dependent and -Independent Pathways , 2005, Molecular Pharmacology.

[99]  M. Chojkier Troglitazone and liver injury: In search of answers , 2005, Hepatology.

[100]  M. Negishi,et al.  Phenobarbital Confers its Diverse Effects by Activating the Orphan Nuclear Receptor Car , 2006, Drug metabolism reviews.

[101]  Paul T Tarr,et al.  Regulation of Multidrug Resistance-associated Protein 2 (ABCC2) by the Nuclear Receptors Pregnane X Receptor, Farnesoid X-activated Receptor, and Constitutive Androstane Receptor* , 2002, The Journal of Biological Chemistry.

[102]  W. Fishman Metabolic conjugation and metabolic hydrolysis , 1970 .

[103]  L. Moore,et al.  2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. , 2003, Biochemistry.

[104]  S. Strom,et al.  Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues. , 2007, Toxicology and applied pharmacology.

[105]  J. Miller,et al.  The metabolism of methylated aminoazo dyes. VI. Intracellular distribution and properties of the demethylase system. , 1957, Cancer research.

[106]  D. Moore,et al.  A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR. , 2004, The Journal of clinical investigation.

[107]  J. Peters,et al.  Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. , 1997, Carcinogenesis.

[108]  J. V. Vanden Heuvel,et al.  Activation of mouse and human peroxisome proliferator-activated receptors (PPARs) by phthalate monoesters. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[109]  Wen Xie,et al.  International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. , 2006, Pharmacological reviews.

[110]  Garet P Lahvis,et al.  Resistance to 2,3,7,8-Tetrachlorodibenzo-p-dioxin Toxicity and Abnormal Liver Development in Mice Carrying a Mutation in the Nuclear Localization Sequence of the Aryl Hydrocarbon Receptor* , 2003, The Journal of Biological Chemistry.

[111]  Johan Auwerx,et al.  Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[112]  D. Moore,et al.  Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. , 2005, Molecular endocrinology.

[113]  G. Perdew,et al.  Use of 2-azido-3-[125I]iodo-7,8-dibromodibenzo-p-dioxin as a probe to determine the relative ligand affinity of human versus mouse aryl hydrocarbon receptor in cultured cells. , 2004, Molecular pharmacology.

[114]  S. Amin,et al.  Cellular and Pharmacological Selectivity of the Peroxisome Proliferator-Activated Receptor-β/δ Antagonist GSK3787 , 2010, Molecular Pharmacology.

[115]  R. Evans,et al.  Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[116]  E. Malle,et al.  Serum amyloid A: An acute-phase protein involved in tumour pathogenesis , 2008, Cellular and Molecular Life Sciences.

[117]  W. Wahli,et al.  Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. , 1996, Endocrinology.

[118]  Raj Kumar,et al.  The structure of the nuclear hormone receptors , 1999, Steroids.

[119]  B. Spiegelman,et al.  mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.

[120]  J. Lehmann,et al.  Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[121]  J. Popp,et al.  Biological potential of basophilic hepatocellular foci and hepatic adenoma induced by the peroxisome proliferator, Wy-14,643. , 1994, Carcinogenesis.

[122]  I. Jutooru,et al.  2-cyano-lup-1-en-3-oxo-20-oic acid, a cyano derivative of betulinic acid, activates peroxisome proliferator-activated receptor gamma in colon and pancreatic cancer cells. , 2007, Carcinogenesis.

[123]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[124]  D. Moore,et al.  The Xenobiotic Compound 1,4-Bis[2-(3,5-Dichloropyridyloxy)]Benzene Is an Agonist Ligand for the Nuclear Receptor CAR , 2000, Molecular and Cellular Biology.

[125]  A. Billin,et al.  PPARbeta/delta ligands as modulators of the inflammatory response. , 2008, Current opinion in investigational drugs.

[126]  R. Ramsden,et al.  Phenobarbital responsiveness conferred by the 5'-flanking region of the rat CYP2B2 gene in transgenic mice. , 1999, Gene.

[127]  Wen Xie,et al.  International Union of Pharmacology. LXII. The NR1H and NR1I Receptors: Constitutive Androstane Receptor, Pregnene X Receptor, Farnesoid X Receptor α, Farnesoid X Receptor β, Liver X Receptor α, Liver X Receptor β, and Vitamin D Receptor , 2006, Pharmacological Reviews.

[128]  B. Hagenbuch Drug Uptake Systems in Liver and Kidney: A Historic Perspective , 2010, Clinical pharmacology and therapeutics.

[129]  R. Evans,et al.  The RXR heterodimers and orphan receptors , 1995, Cell.

[130]  L. Perera,et al.  Dephosphorylation of Threonine 38 Is Required for Nuclear Translocation and Activation of Human Xenobiotic Receptor CAR (NR1I3)* , 2009, The Journal of Biological Chemistry.

[131]  Masayuki Yamamoto,et al.  Effects of Aryl Hydrocarbon Receptor Signaling on the Modulation of Th1/Th2 Balance1 , 2005, The Journal of Immunology.

[132]  C. Wolf,et al.  A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. , 2008, The Journal of clinical investigation.

[133]  C. Falany,et al.  Regulation of Human Hepatic Hydroxysteroid Sulfotransferase Gene Expression by the Peroxisome Proliferator-Activated Receptor α Transcription Factor , 2005, Molecular Pharmacology.

[134]  J. Heuvel Diet, fatty acids, and regulation of genes important for heart disease , 2004 .

[135]  C. Waller,et al.  Three-dimensional quantitative structure-activity relationships of dioxins and dioxin-like compounds: model validation and Ah receptor characterization. , 1995, Chemical research in toxicology.

[136]  J. Auwerx,et al.  The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene* , 1997, The Journal of Biological Chemistry.

[137]  W. Wahli,et al.  Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. , 2002, Molecular cell.

[138]  R. Evans,et al.  Interactions between Hepatic Mrp4 and Sult2a as Revealed by the Constitutive Androstane Receptor and Mrp4 Knockout Mice* , 2004, Journal of Biological Chemistry.

[139]  C. Handschin,et al.  Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. , 2005, Archives of biochemistry and biophysics.

[140]  S. Amin,et al.  Evidence for Ligand-Mediated Selective Modulation of Aryl Hydrocarbon Receptor Activity , 2010, Molecular Pharmacology.

[141]  A. Burdick,et al.  The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. , 2006, Cellular signalling.

[142]  C. Wolf,et al.  Human constitutive androstane receptor (CAR) and pregnane X receptor (PXR) support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogens phenobarbital and chlordane in vivo. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[143]  T. Willson,et al.  PPARβ/δ selectively induces differentiation and inhibits cell proliferation , 2006, Cell Death and Differentiation.

[144]  S. Amin,et al.  Characterization of the antiallergic drugs 3-[2-(2-phenylethyl) benzoimidazole-4-yl]-3-hydroxypropanoic acid and ethyl 3-hydroxy-3-[2-(2-phenylethyl)benzoimidazol-4-yl]propanoate as full aryl hydrocarbon receptor agonists. , 2008, Chemical research in toxicology.

[145]  W. Wahli,et al.  Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progression , 2006, Proceedings of the National Academy of Sciences.

[146]  S Kettle,et al.  Mechanistically-based Human Hazard Assessment of Peroxisome Proliferator-induced Hepatocarcinogenesis , 1994, Human & experimental toxicology.

[147]  G. Perdew,et al.  Ligand Selectivity and Gene Regulation by the Human Aryl Hydrocarbon Receptor in Transgenic Mice , 2009, Molecular Pharmacology.

[148]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[149]  S. Lien,et al.  Identification of a Novel Peroxisome Proliferator-Activated Receptor (PPAR) γ Promoter in Man and Transactivation by the Nuclear Receptor RORα1 , 2001 .

[150]  Laura Bonati,et al.  Evidence that ligand binding is a key determinant of Ah receptor-mediated transcriptional activity. , 2005, Archives of biochemistry and biophysics.

[151]  Y. Yano,et al.  Peroxisome proliferator‐activated receptor δ as a molecular target to regulate lung cancer cell growth , 2005 .

[152]  J. Auwerx,et al.  PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. , 1998, FEBS letters.

[153]  Wen Xie,et al.  PXR and CAR in energy metabolism , 2009, Trends in Endocrinology & Metabolism.

[154]  Jiandie D. Lin,et al.  Nutritional Regulation of Hepatic Heme Biosynthesis and Porphyria through PGC-1α , 2005, Cell.

[155]  S. Safe,et al.  Substituted flavones as aryl hydrocarbon (Ah) receptor agonists and antagonists. , 1996, Biochemical pharmacology.

[156]  K. Willecke,et al.  Lack of phenobarbital-mediated promotion of hepatocarcinogenesis in connexin32-null mice. , 2000, Cancer research.

[157]  M. Negishi,et al.  CAR and PXR: The xenobiotic-sensing receptors , 2007, Steroids.

[158]  J. Ward,et al.  Peroxisome proliferator‐activated receptor‐β/δ protects against chemically induced liver toxicity in mice , 2007 .

[159]  G. Perdew,et al.  Ah receptor represses acute phase response gene expression without binding to its cognate response element , 2009, Laboratory Investigation.

[160]  D. Nelson The Cytochrome P450 Homepage , 2009, Human Genomics.

[161]  G. Perdew,et al.  The aryl hydrocarbon receptor complex and the control of gene expression. , 2008, Critical reviews in eukaryotic gene expression.

[162]  M. Veldhoen,et al.  Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells , 2009, The Journal of experimental medicine.

[163]  J. Reddy,et al.  Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. , 1983, Critical reviews in toxicology.

[164]  Oliver Burk,et al.  Antimalarial Artemisinin Drugs Induce Cytochrome P450 and MDR1 Expression by Activation of Xenosensors Pregnane X Receptor and Constitutive Androstane Receptor , 2005, Molecular Pharmacology.

[165]  L. Moore,et al.  Identification of a Novel Human Constitutive Androstane Receptor (CAR) Agonist and Its Use in the Identification of CAR Target Genes* , 2003, The Journal of Biological Chemistry.

[166]  J. Auwerx,et al.  Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[167]  H. Isomäki,et al.  Decrease in the number of deaths from secondary amyloidosis in patients with juvenile rheumatoid arthritis. , 1993, The Journal of rheumatology.

[168]  B. Staels,et al.  Peroxisome Proliferator-activated Receptor α Induces Hepatic Expression of the Human Bile Acid Glucuronidating UDP-glucuronosyltransferase 2B4 Enzyme* , 2003, Journal of Biological Chemistry.

[169]  S. Auerbach,et al.  Alternatively spliced isoforms of the human constitutive androstane receptor. , 2003, Nucleic acids research.

[170]  Ying Zheng,et al.  PPARbeta/delta agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-kappaB signals. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[171]  D. Moore,et al.  Modulation of Acetaminophen-Induced Hepatotoxicity by the Xenobiotic Receptor CAR , 2002, Science.

[172]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. , 1994, Cell.

[173]  R. Evans,et al.  Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.

[174]  L. Moore,et al.  Orphan Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Share Xenobiotic and Steroid Ligands* , 2000, The Journal of Biological Chemistry.

[175]  Hongbing Wang,et al.  Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 Inducers , 2007, Journal of Pharmacology and Experimental Therapeutics.

[176]  Y. Wan,et al.  PPAR-γ regulates osteoclastogenesis in mice , 2007, Nature Medicine.

[177]  S. Duensing,et al.  A novel role of the aryl hydrocarbon receptor (AhR) in centrosome amplification - implications for chemoprevention , 2010, Molecular Cancer.

[178]  Y. Fujii‐Kuriyama,et al.  Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells , 2008, Proceedings of the National Academy of Sciences.

[179]  S. Auerbach,et al.  Retinoid X Receptor-α-Dependent Transactivation by a Naturally Occurring Structural Variant of Human Constitutive Androstane Receptor (NR1I3) , 2005, Molecular Pharmacology.

[180]  D. Waxman,et al.  Synthetic Drugs and Natural Products as Modulators of Constitutive Androstane Receptor (Car) and Pregnane X Receptor (PXR) , 2006, Drug metabolism reviews.

[181]  H. Remmer Die Beschleunigung der Evipanoxydation und der Demethylierung von Methylaminoantipyrin durch Barbiturate , 2004, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.

[182]  G. Prendergast,et al.  Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase , 2008, Proceedings of the National Academy of Sciences.

[183]  C. Glass,et al.  The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.

[184]  T. Omura,et al.  A new cytochrome in liver microsomes. , 1962, The Journal of biological chemistry.

[185]  Reena Rao,et al.  Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption , 2005, Nature Medicine.

[186]  D. Schrenk,et al.  Carcinogenicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in experimental models. , 2006, Molecular nutrition & food research.

[187]  Béatrice Desvergne,et al.  Peroxisome-proliferator-activated receptors and cancers: complex stories , 2004, Nature Reviews Cancer.

[188]  G. Ailhaud,et al.  Cloning of a Protein That Mediates Transcriptional Effects of Fatty Acids in Preadipocytes , 1995, The Journal of Biological Chemistry.

[189]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[190]  S. Kliewer,et al.  Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. , 2002, Molecular pharmacology.

[191]  M E Hurtt,et al.  Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[192]  K. Kawajiri,et al.  Zinc finger transcription factor Slug is a novel target gene of aryl hydrocarbon receptor. , 2006, Experimental cell research.

[193]  J. Ward,et al.  Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. , 2006, Carcinogenesis.

[194]  P. Neuvonen,et al.  Cancer incidence among patients using antiepileptic drugs: a long-term follow-up of 28,000 patients , 2002, European Journal of Clinical Pharmacology.

[195]  M. Negishi,et al.  CAR, driving into the future. , 2004, Molecular endocrinology.

[196]  A. Hevener,et al.  PPARdelta regulates glucose metabolism and insulin sensitivity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[197]  D. Moore,et al.  A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements , 1994, Molecular and cellular biology.

[198]  Josephine C. Adams,et al.  Fascin-1 Promoter Activity Is Regulated by CREB and the Aryl Hydrocarbon Receptor in Human Carcinoma Cells , 2009, PloS one.

[199]  Vicki L Dellarco,et al.  Mode of action in relevance of rodent liver tumors to human cancer risk. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[200]  M. Denison,et al.  Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. , 2003, Annual review of pharmacology and toxicology.

[201]  B. Rigas,et al.  Regulation of peroxisome proliferator‐activated receptor‐β/δ by the APC/β‐CATENIN pathway and nonsteroidal antiinflammatory drugs , 2009, Molecular carcinogenesis.

[202]  A. Ferko,et al.  [Pigmented hepatocellular adenoma of the liver caused by long-term use of phenobarbital]. , 2003, Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti.

[203]  T. Imazawa,et al.  Promoting effect of peroxisome proliferators in two-stage rat renal tumorigenesis. , 1988, Cancer letters.

[204]  T. Willson,et al.  The Nuclear Receptor CAR Is a Regulator of Thyroid Hormone Metabolism during Caloric Restriction* , 2004, Journal of Biological Chemistry.

[205]  S. Mulero-Navarro,et al.  The dioxin receptor regulates the constitutive expression of the vav3 proto-oncogene and modulates cell shape and adhesion. , 2009, Molecular biology of the cell.

[206]  Y Fujii-Kuriyama,et al.  Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors. , 1994, The Journal of biological chemistry.

[207]  T. Willson,et al.  Ligand activation of peroxisome proliferator-activated receptor-beta/delta(PPARbeta/delta) inhibits cell growth of human N/TERT-1 keratinocytes. , 2007, Cellular signalling.

[208]  T. Boyer Special article the glutathione S‐transferases: An update , 1989 .

[209]  Masayuki Yamamoto,et al.  Intrinsic Function of the Aryl Hydrocarbon (Dioxin) Receptor as a Key Factor in Female Reproduction , 2005, Molecular and Cellular Biology.

[210]  C. Long,et al.  PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs. , 2005, American journal of physiology. Heart and circulatory physiology.

[211]  M. Gallo,et al.  Ah receptor and NF-kappaB interactions, a potential mechanism for dioxin toxicity. , 1999, The Journal of biological chemistry.

[212]  L. Moore,et al.  A Structural Basis for Constitutive Activity in the Human CAR/RXRα Heterodimer , 2004 .

[213]  A. Billin PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. , 2008, Expert opinion on investigational drugs.

[214]  Y. Okada,et al.  Activation of the aryl hydrocarbon receptor pathway enhances cancer cell invasion by upregulating the MMP expression and is associated with poor prognosis in upper urinary tract urothelial cancer. , 2010, Carcinogenesis.

[215]  K. Umesono,et al.  Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[216]  J. Lehmann,et al.  The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.

[217]  M. Redinbo,et al.  Structural insights into the promiscuity and function of the human pregnane X receptor. , 2002, Current opinion in drug discovery & development.

[218]  R. Pyzalski,et al.  The Aryl Hydrocarbon Receptor Is Required for Developmental Closure of the Ductus Venosus in the Neonatal Mouse , 2005, Molecular Pharmacology.

[219]  M. Klingenberg Pigments of rat liver microsomes. , 2003, Archives of biochemistry and biophysics.

[220]  J. Auwerx,et al.  PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter , 1998 .

[221]  Alfonso Lampen,et al.  Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. , 2005, Carcinogenesis.

[222]  S. Amin,et al.  Effect of ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in human lung cancer cell lines. , 2008, Toxicology.

[223]  J. Peters,et al.  Role of peroxisome-proliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and disease. , 2008, Clinical science.

[224]  A. Y. Lu,et al.  CYP1A Induction and Human Risk Assessment: An Evolving Tale of in Vitro and in Vivo Studies , 2007, Drug Metabolism and Disposition.

[225]  Sung-Dae Cho,et al.  Peroxisome proliferator-activated receptor γ-dependent activity of indole ring-substituted 1,1-bis(3′-indolyl)-1-(p-biphenyl)methanes in cancer cells , 2010, Cancer Chemotherapy and Pharmacology.

[226]  R. T. Williams,et al.  HISTORY OF THE DISCOVERY OF THE CONJUGATION MECHANISMS , 1970 .

[227]  S. Amin,et al.  Development of a selective modulator of aryl hydrocarbon (Ah) receptor activity that exhibits anti-inflammatory properties. , 2010, Chemical research in toxicology.

[228]  J. Lehmann,et al.  An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway , 1998, Cell.

[229]  P. Limburg,et al.  Rapid automated enzyme immunoassay of serum amyloid A. , 1994, Clinical chemistry.

[230]  O. Braissant,et al.  Differential Expression of Peroxisome Proliferator-Activated Receptor- , - , and - during Rat Embryonic Development , 1998 .

[231]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[232]  Y. Yano,et al.  Peroxisome proliferator-activated receptor delta as a molecular target to regulate lung cancer cell growth. , 2005, FEBS letters.

[233]  T. P. Krishnakantha,et al.  Hepatic peroxisome proliferation: induction by two novel compounds structurally unrelated to clofibrate , 1975, Science.

[234]  S. Ryu,et al.  Serum Amyloid A Binding to Formyl Peptide Receptor-Like 1 Induces Synovial Hyperplasia and Angiogenesis1 , 2006, The Journal of Immunology.

[235]  A. Mahfoudi,et al.  Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[236]  S. Kliewer,et al.  Use of the nuclear receptor PXR to predict drug interactions. , 2000, Toxicology.

[237]  R. Flavell,et al.  Nuclear Receptor CAR Represses TNFα-Induced Cell Death by Interacting with the Anti-Apoptotic GADD45B , 2010, PloS one.

[238]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[239]  L. Moore,et al.  A structural basis for constitutive activity in the human CAR/RXRalpha heterodimer. , 2004, Molecular cell.

[240]  G. Perdew,et al.  Mechanistic Insights into the Events That Lead to Synergistic Induction of Interleukin 6 Transcription upon Activation of the Aryl Hydrocarbon Receptor and Inflammatory Signaling , 2010, The Journal of Biological Chemistry.

[241]  N. Mitro,et al.  T0901317 is a potent PXR ligand: Implications for the biology ascribed to LXR , 2007, FEBS letters.

[242]  F. Guengerich,et al.  Purification and characterization of liver microsomal cytochromes p-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or beta-naphthoflavone. , 1982, Biochemistry.

[243]  T. Gasiewicz,et al.  Expression and activity of aryl hydrocarbon receptors in development and cancer. , 2008, Critical reviews in eukaryotic gene expression.

[244]  R. Evans,et al.  The Constitutive Androstane Receptor and Pregnane X Receptor Function Coordinately to Prevent Bile Acid-induced Hepatotoxicity* , 2004, Journal of Biological Chemistry.

[245]  A. Peck,et al.  Breaking old paradigms: Th17 cells in autoimmune arthritis. , 2009, Clinical immunology.

[246]  J. Ward,et al.  Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. , 2008, Hepatology.

[247]  J. Pascussi,et al.  Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. , 2008, Molecular pharmaceutics.

[248]  Reddy Jk,et al.  Carcinogenesis by Hepatic Peroxisome Proliferators: Evaluation of the Risk of Hypolipidemic Drugs and Industrial Plasticizers to Humans , 1983 .

[249]  D. Moore,et al.  Differential Transactivation by Two Isoforms of the Orphan Nuclear Hormone Receptor CAR* , 1997, The Journal of Biological Chemistry.

[250]  N. Sládek,et al.  Evidence for a new P-450 hemoprotein in hepatic microsomes from methylcholanthrene treated rats. , 1966, Biochemical and biophysical research communications.

[251]  S. Lien,et al.  Identification of a novel peroxisome proliferator-activated receptor (PPAR) gamma promoter in man and transactivation by the nuclear receptor RORalpha1. , 2001, Biochemical and biophysical research communications.

[252]  J. Caldwell Conjugation Mechanisms of Xenobiotic Metabolism: Mammalian Aspects , 1986 .

[253]  J. Lehmann,et al.  Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. , 2002, Molecular pharmacology.

[254]  Ayumi Kasai,et al.  Cigarette smoke as a trigger for the dioxin receptor-mediated signaling pathway. , 2007, Cancer letters.

[255]  Bradley L Urquhart,et al.  Nuclear Receptors and the Regulation of Drug‐Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs , 2007, Journal of clinical pharmacology.

[256]  C. Koike,et al.  Nuclear Receptors CAR and PXR Cross Talk with FOXO1 To Regulate Genes That Encode Drug-Metabolizing and Gluconeogenic Enzymes , 2004, Molecular and Cellular Biology.

[257]  S. O’Rahilly,et al.  PPARγ and human metabolic disease , 2006 .

[258]  A. Anderson,et al.  Localization of a phenobarbital-responsive element (PBRE) in the 5'-flanking region of the rat CYP2B2 gene. , 1995, Gene.

[259]  O. Hankinson The aryl hydrocarbon receptor complex. , 1995, Annual review of pharmacology and toxicology.

[260]  W. Wahli,et al.  Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. , 2001, Endocrinology.

[261]  J. Gustafsson,et al.  Interactions of indolo[3,2-b]carbazoles and related polycyclic aromatic hydrocarbons with specific binding sites for 2,3,7,8-tetrachlorodibenzo-p-dioxin in rat liver. , 1993, Molecular pharmacology.

[262]  J. Preiß,et al.  Adverse Health Effects in Humans Exposed to 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) , 2006, Reviews on environmental health.

[263]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.

[264]  S. Ha,et al.  Decrease in the number of deaths from secondary amyloidosis in patients with juvenile rheumatoid arthritis. , 1993 .

[265]  C. Glass,et al.  PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[266]  Jerrold M. Olefsky,et al.  PPARδ regulates glucose metabolism and insulin sensitivity , 2006 .

[267]  James E Klaunig,et al.  PPARalpha agonist-induced rodent tumors: modes of action and human relevance. , 2003, Critical reviews in toxicology.

[268]  Yonggong Zhai,et al.  The Constitutive Androstane Receptor Is an Anti-obesity Nuclear Receptor That Improves Insulin Sensitivity* , 2009, The Journal of Biological Chemistry.

[269]  Garet P Lahvis,et al.  Abnormal Liver Development and Resistance to 2,3,7,8-Tetrachlorodibenzo-p-Dioxin Toxicity in Mice Carrying a Mutation in the DNA-Binding Domain of the Aryl Hydrocarbon Receptor , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[270]  P. Harper,et al.  Characterization of the Ah receptor and aryl hydrocarbon hydroxylase induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin and benz(a)anthracene in the human A431 squamous cell carcinoma line. , 1988, Cancer research.

[271]  T. Willson,et al.  Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist. , 2010, Journal of Medicinal Chemistry.

[272]  L. Moore,et al.  St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[273]  J. Schlezinger,et al.  Aryl hydrocarbon receptor (AhR) agonists suppress interleukin-6 expression by bone marrow stromal cells: an immunotoxicology study , 2003, Environmental health : a global access science source.

[274]  R. Maronpot,et al.  The Orphan Nuclear Receptor Constitutive Active/Androstane Receptor Is Essential for Liver Tumor Promotion by Phenobarbital in Mice , 2004, Cancer Research.

[275]  I. Rusyn,et al.  Genomic Profiling in Nuclear Receptor-Mediated Toxicity , 2007, Toxicologic pathology.

[276]  M. Krasowski,et al.  Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. , 2006, Current drug metabolism.

[277]  C. J. Omiecinski,et al.  Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[278]  T. Willson,et al.  Ligand activation of peroxisome proliferator-activated receptor-β/δ(PPARβ/δ) inhibits cell growth of human N/TERT-1 keratinocytes , 2007 .

[279]  T. Willson,et al.  Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity. , 2003, Bioorganic & medicinal chemistry letters.

[280]  W. Wahli,et al.  DNA Binding Properties of Peroxisome Proliferator-activated Receptor Subtypes on Various Natural Peroxisome Proliferator Response Elements , 1997, The Journal of Biological Chemistry.